WELCOME TO The Biotechnology REPORT
North Spring Behavioral Healthcare
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
BioMarin | November 18, 2020
BioMarin Pharmaceutical Inc. and Deep Genomics declares that the organizations have gone into a preclinical collaboration that will use Deep Genomics' artificial intelligence drug discovery platform (The AI Workbench) to distinguish oligonucleotide drug applicants in four uncommon sickness signs with high neglected need. Deep Genomics will get an undisclosed forthright installment and is qualified to get improvement achievements as a piece of the coordinated effort. BioMarin will get an elit...
BioSpace | March 12, 2020
Tyligand Bioscience, Ltd., a leader in small molecule drug discovery and development, and Context Therapeutics LLC, a clinical stage biopharmaceutical company focused on hormone driven cancers, today announced the signing of collaboration agreements for the development, manufacturing, registration and future commercialization of onapristone extended release (ER). Onapristone ER is currently being evaluated in patients with progesterone receptor positive (PR+) ovarian and endometrial cancers in t...
Cell and Gene Therapy
HDT Bio Corp. | January 17, 2022
HDT Bio Corp., a U.S. developer of immunotherapies for oncology and infectious diseases and SENAI CIMATEC, an important Brazilian education, research, and innovation institute, have dosed the first healthy volunteers in Brazil in a Phase 1 trial of HDT Bio’s RNA COVID-19 vaccine, HDT-301. SENAI CIMATEC will conduct the clinical trial under the name Vaccine RNA MCTI-CIMATEC-HDT. The vaccine uses HDT Bio’s proprietary lipid nanoparticle RNA-delivery technology.
BioAge Labs, Inc. | August 24, 2022
BioAge Labs, Inc. a biotechnology company developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, today announced that it has initiated a partnership agreement with Age Labs AS a diagnostic company that develops tests for the early detection of age-related diseases. Under the terms of the agreement, BioAge will perform multi-omics analyses on samples and health records from the Nord-Trøndelag Health Study biobank collected from more than 100,000...
Cell and Gene Therapy, Industrial Impact
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE